| ID | Peptide Seq | Site Residue | Position in Peptide | Position in Protein |
|---|---|---|---|---|
| 10000559 | EEKPAVTAAPK | T | 7 | 170 |
| 10002040 | 162 | |||
| 10006077 | PAVTAAPKK | T | 4 | 170 |
| 10015054 | EEKPAVTAAPK | T | 7 | 170 |
| 10025781 | EEKPAVTAAPK | T | 7 | 170 |
| ID | Method | Analytical Throughput | Ambiguity | Species | Sample Type | Condition | log2Ratio | P Value | Data Source PMID | Comments |
|---|---|---|---|---|---|---|---|---|---|---|
| 10000559 | MS | HTP | unambiguous | human | brain | Alzheimers disease/control | None | 0.462357466 | 28657654 | |
| 10002040 | MS | HTP | unambiguous | human | HeLa cells | Interphase/Mitosis | None | 34161081 | The p value was -log10p in original paper. | |
| 10006077 | prediction and site-directed mutagenesis | LTP | unambiguous | human | U-118 MG cells | None | 26620801 | No mass spec. data provided; the peptide sequence is inferredfrom tryptic cleavage | ||
| 10015054 | MS | HTP | unambiguous | human | HeLa cells | None | 31492838 | |||
| 10025781 | MS | HTP | unambiguous | human | HeLa cells | None | 35254053 |
| ID | Peptide Seq | Site Residue | Position in Peptide | Position in Protein | Method | Analytical Throughput | Ambiguity | Species | Sample Type | Data Source PMID | Comments |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 10000559 | EEKPAVTAAPK | T | 7 | 170 | MS | HTP | unambiguous | human | brain | 28657654 | |
| 10002040 | 162 | MS | HTP | unambiguous | human | HeLa cells | 34161081 | The p value was -log10p in original paper. | |||
| 10006077 | PAVTAAPKK | T | 4 | 170 | prediction and site-directed mutagenesis | LTP | unambiguous | human | U-118 MG cells | 26620801 | No mass spec. data provided; the peptide sequence is inferredfrom tryptic cleavage |
| 10015054 | EEKPAVTAAPK | T | 7 | 170 | MS | HTP | unambiguous | human | HeLa cells | 31492838 | |
| 10025781 | EEKPAVTAAPK | T | 7 | 170 | MS | HTP | unambiguous | human | HeLa cells | 35254053 |